Risk of Lymphoma Associated with Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: Implications for Therapy

被引：35

作者：

Dahmus, Jessica ^{[1
]}

Rosario, Michelle ^{[1
]}

Clarke, Kofi ^{[1
]}

机构：

[1] Penn State Milton S Hershey Med Ctr, Gastroenterol, Hershey, PA 17033 USA

来源：

CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY | 2020年 / 13卷

关键词：

malignancy; cancer; biologics; ulcerative colitis; Crohn's disease; hepatosplenic T-cell lymphoma; TUMOR-NECROSIS-FACTOR; EVIDENCE-BASED CONSENSUS; CROHNS-DISEASE; CANCER-RISK; THIOPURINES; INFLIXIMAB; IMMUNOMODULATORS; MALIGNANCIES; ANTAGONISTS; INFECTIONS;

D O I：

10.2147/CEG.S237646

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Anti-tumor necrosis factor alpha (ATA) therapy plays a significant role in the treatment of moderate to severe inflammatory bowel disease (IBD). There are concerns regarding risks associated with their use, including malignancy and, specifically, lymphoma. Many previous studies have sought to determine whether there is a true link between ATA therapy in IBD and development of lymphoma. However they have been hindered by short follow-up times, few cases, and confounding factors such as previous thiopurine exposure. This review seeks to update the literature by evaluating more recent studies assessing the link between ATA monotherapy and lymphoma development. It also summarizes findings of those studies and provides additional clinical guidance pertaining to this class of biologic therapy.

引用

页码：339 / 350

页数：12

共 44 条

[1] Risk Factors for Lymphoma in Patients with Inflammatory Bowel Disease: A Case-control Study [J].

Afif, Waqqas ;

Sandborn, William J. ;

Faubion, William A. ;

Rahman, Meher ;

Harmsen, Scott W. ;

Zinsmeister, Alan R. ;

Loftus, Edward V., Jr. .

INFLAMMATORY BOWEL DISEASES, 2013, 19 (07) :1384-1389

[2] Association Between Tumor Necrosis Factor-α Antagonists and Risk of Cancer in Patients With Inflammatory Bowel Disease [J].

Andersen, Nynne Nyboe ;

Pasternak, Bjorn ;

Basit, Saima ;

Andersson, Mikael ;

Svanstrom, Henrik ;

Caspersen, Sarah ;

Munkholm, Pia ;

Hviid, Anders ;

Jess, Tine .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (23) :2406-2413

[3] European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies [J].

Annese, Vito ;

Beaugerie, Laurent ;

Egan, Laurence ;

Biancone, Livia ;

Bolling, Claus ;

Brandts, Christian ;

Dierickx, Daan ;

Dummer, Reinhard ;

Fiorino, Gionata ;

Gornet, Jean Marc ;

Higgins, Peter ;

Katsanos, Konstantinos H. ;

Nissen, Loes ;

Pellino, Gianluca ;

Rogler, Gerhard ;

Scaldaferri, Franco ;

Szymanska, Edyta ;

Eliakim, Rami .

JOURNAL OF CROHNS & COLITIS, 2015, 9 (11) :945-965

[4] Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents [J].

Axelrad, Jordan ;

Bernheim, Oren ;

Colombel, Jean-Frederic ;

Malerba, Stefano ;

Ananthakrishnan, Ashwin ;

Yajnik, Vijay ;

Hoffman, Gila ;

Agrawal, Manasi ;

Lukin, Dana ;

Desai, Amit ;

McEachern, Elisa ;

Bosworth, Brian ;

Scherl, Ellen ;

Reyes, Andre ;

Zaidi, Hina ;

Mudireddy, Prashant ;

DiCaprio, David ;

Sultan, Keith ;

Korelitz, Burton ;

Wang, Erwin ;

Williams, Renee ;

Chen, LeaAnn ;

Katz, Seymour ;

Itzkowitz, Steven .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (01) :58-64

[5] Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study [J].

Beaugerie, Laurent ;

Brousse, Nicole ;

Bouvier, Anne Marie ;

Colombel, Jean Frederic ;

Lemann, Marc ;

Cosnes, Jacques ;

Hebuterne, Xavier ;

Cortot, Antoine ;

Bouhnik, Yoram ;

Gendre, Jean Pierre ;

Simon, Tabassome ;

Maynadie, Marc ;

Hermine, Olivier ;

Faivre, Jean ;

Carrat, Fabrice .

LANCET, 2009, 374 (9701) :1617-1625

[6] Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies [J].

Beigel, Florian ;

Steinborn, Anni ;

Schnitzler, Fabian ;

Tillack, Cornelia ;

Breiteneicher, Simone ;

John, Jestinah Mahachie ;

Van Steen, Kristel ;

Laubender, Ruediger P. ;

Goeke, Burkhard ;

Seiderer, Julia ;

Brand, Stephan ;

Ochsenkuehn, Thomas .

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 (07) :735-744

[7] Lymphoproliferative Disorders in Inflammatory Bowel Disease Patients: Is It the Drugs or the Disease [J].

Bernardes, Carlos ;

Russo, Pedro ;

Carvalho, Diana ;

Saiote, Joana ;

Ramos, Jaime .

GE PORTUGUESE JOURNAL OF GASTROENTEROLOGY, 2018, 25 (04) :175-178

[8] Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study [J].

Biancone, Livia ;

Armuzzi, Alessandro ;

Scribano, Maria Lia ;

D'Inca, Renata ;

Castiglione, Fabiana ;

Papi, Claudio ;

Angelucci, Erika ;

Daperno, Marco ;

Mocciaro, Filippo ;

Riegler, Gabriele ;

Fries, Walter ;

Meucci, Gianmichele ;

Alvisi, Patrizia ;

Spina, Luisa ;

Ardizzone, Sandro ;

Petruzziello, Carmelina ;

Ruffa, Alessandra ;

Kohn, Anna ;

Vecchi, Maurizio ;

Guidi, Luisa ;

Di Mitri, Roberto ;

Renna, Sara ;

Emma, Calabrese ;

Rogai, Francesca ;

Rossi, Alessandra ;

Orlando, Ambrogio ;

Pallone, Francesco .

JOURNAL OF CROHNS & COLITIS, 2016, 10 (08) :913-924

[9] Tumor necrosis factor antagonist therapy and lymphoma development - Twenty-six cases reported to the Food and Drug Administration [J].

Brown, SL ;

Greene, MH ;

Gershon, SK ;

Edwards, ET ;

Braun, MM .

ARTHRITIS AND RHEUMATISM, 2002, 46 (12) :3151-3158

[10] Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints - Extended report [J].

Catrina, AI ;

Trollmo, C ;

af Klint, E ;

Engstrom, M ;

Lampa, J ;

Hermansson, Y ;

Klareskog, L ;

Ulfgren, AK .

ARTHRITIS AND RHEUMATISM, 2005, 52 (01) :61-72

← 1 2 3 4 5 →